Dear Author,

Here are the final proofs of your article. Please check the proofs carefully.

All communications with regard to the proof should be sent to <a href="mailto:bmcproductionteam2@spi-global.com">bmcproductionteam2@spi-global.com</a>.

Please note that at this stage you should only be checking for errors introduced during the production process. Please pay particular attention to the following when checking the proof:

- Author names. Check that each author name is spelled correctly, and that names appear in the correct order of first name followed by family name. This will ensure that the names will be indexed correctly (for example if the author's name is 'Jane Patel', she will be cited as 'Patel, J.').
- Affiliations. Check that all authors are cited with the correct affiliations, that the author who will receive correspondence has been identified with an asterisk (\*), and that all equal contributors have been identified with a dagger sign (†).
- Ensure that the main text is complete.
- Check that figures, tables and their legends are included and in the correct order.
- Look to see that queries that were raised during copy-editing or typesetting have been resolved.
- Confirm that all web links are correct and working.
- Ensure that special characters and equations are displaying correctly.
- Check that additional or supplementary files can be opened and are correct.

<u>Changes in scientific content cannot be made at this stage unless the request has already been approved</u>. This includes changes to title or authorship, new results, or corrected values.

# How to return your corrections

Returning your corrections via online submission:

- Please provide details of your corrections in the online correction form. Always indicate the line number to which the correction refers.

Returning your corrections via email:

- Annotate the proof PDF with your corrections.
- Send it as an email attachment to: <u>bmcproductionteam2@spi-global.com</u>.
- Remember to include the journal title, manuscript number, and your name when sending your response via email.

Note: in order to ensure timely publication, if we do not hear from you within 48 hours we may take the decision to sign-off the article on your behalf and proceed to publication.

After you have submitted your corrections, you will receive email notification from our production team that your article has been published in the final version. <u>All changes at this stage are final.</u> We will not be able to make any further changes after publication.

Kind regards,

BioMed Central Production Team 2



**CASE REPORT Open Access** 

# Synchronous primary neoplasms of the bladder, skin and breast in a male patient: a case report

- Antonio Luigi Pastore<sup>1\*</sup>, Giovanni Palleschi<sup>1</sup>, Domenico Autieri<sup>1</sup>, Antonino Leto<sup>1</sup>, Andrea Ripoli<sup>1</sup>, Cristina Maggioni<sup>1</sup>,
- Davide Moschese<sup>1</sup>, Yazan Al Salhi<sup>1</sup>, Natale Porta<sup>2</sup>, Claudio Di Cristofano<sup>2</sup>, Andrea Fuschi<sup>1</sup>, Luigi Silvestri<sup>1</sup>, 5
- Carlo Della Rocca<sup>2</sup>, Silverio Tomao<sup>3</sup>, Vincenzo Petrozza<sup>2</sup>, Antonio Carbone<sup>1</sup> and Sapienza University of Rome,
- Faculty of Pharmacy and Medicine

### **Abstract**

11

12

13

14

15

16

17

18 19

20

21

22

23 24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

The incidence of multiple primary malignant neoplasms increases with age, reflecting an increase in overall cancer risk in older patients. Cases of two or more concurrent primary cancers are still rare, although its incidence is increasing. Here, we report the case of a 57-year-old man who was referred to our institution with synchronous squamous cell carcinoma of the skin on the forehead, infiltrating ductal carcinoma of the breast, and transitional cell carcinoma of the urinary bladder. To the best of our knowledge, this is the first reported case in literature of this combination of primary neoplasms.

# **Background**

Multiple primary cancers (MPC) in a single patient was first documented by Billroth et al. in 1889 [1]. Since then, many cases of double, triple or even quintuple primary malignant neoplasms have been documented involving single or multiple organs [2]. MPCs are first classified as either synchronous or metachronous depending on their timing of diagnosis. Synchronous lesions are relatively uncommon, with most cases involving metachronous lesions [3,4].

However, there remains some confusion over the terms used to describe MPC, such as synchronous, simultaneous, and metachronous or successive neoplasms. All these definitions are based on the time that the neoplasms are discovered rather than the onset of disease. Thus, the term 'synchronous' refers to neoplasms discovered simultaneously, while 'metachronous' indicates a distinct neoplasm discovered when the same patient is already known to have a neoplasm (successive neoplasm) [5].

The generally accepted definition of MPC was introduced by Worren and Gates, who stated that each neoplasm must represent a distinct malignancy, and that a

In this report, we describe the case of a patient who 43 developed synchronous primary transitional cell carcin- 44 oma (TCC) of the urinary bladder, squamous cell car- 45 cinoma (SCC) of the skin on the forehead, and 46 infiltrating ductal breast carcinoma. This combination, 47 to the best of our knowledge, has never previously been reported in the literature.

49

50

# **Case presentation**

A 57-year-old man, a farmer and heavy smoker (90 to 51 100 cigarettes a day from the age of 15 years), was re- 52 ferred to our institute for gross haematuria with cloths 53 retention that required an acute catheterisation with 54 bladder irrigation. An ultrasound examination showed 55 papillary neoplasms arising from the posterior-lateral left 56 wall of the bladder.

The patient had suffered lower urinary tract symptoms 58 over the preceding 1 year and seemed cachectic, but had 59 not previously reported weight loss or any other specific 60 complaints. He did have a family history of malignancy 61 though, as his father had developed rectal cancer and his 62 sister had a kidney neoplasm.


He had no signs or symptoms until his physician noticed a hard lump with skin retraction on his left nipple. 65

<sup>&</sup>lt;sup>1</sup>Department of Medical and Surgical Sciences and Biotechnologies, Unit of Urology, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Corso della Repubblica 79, 04100, Latina, (LT), Italy Full list of author information is available at the end of the article



metastatic origin must be excluded [6]. Ray et al. 40 reported that 13.5% patients with MPC had genitouri- 41 nary neoplasms [7].

<sup>\*</sup> Correspondence: antopast@hotmail.com



**Figure 1 Malignant breast neoplasia. (A)** Low-power photomicrograph breast epithelial proliferation mainly organized in solid nests and cords, with occasional pseudoglandular aspects (magnification 4x); **(B)** High-power photomicrograph showing epithelial cells of medium-great size, with altered nucleus-cytoplasm ratio, leptocromatinic nucleus, nucleolus often prominent and large eosinophilic cytoplasm (magnification 40x); the cell showed immunoreactivity for GCDFP-15 **(C)**, CK7 **(D)** and ER **(E)** (magnification 40x).

The patient also had an erythematous nodular skin lesion developing on his forehead. For these lesions, the patient underwent left modified radical mastectomy (based on the Madden technique) with axillary lymph node dissection. Histopathological examination revealed an infiltrating ductal carcinoma (grade III, score 8 according to Nottingham) with metastasis to one of the 11 axillary lymph nodes examined. Approximately 90% of the neoplastic cells stained positive with antibody to the oestrogen receptor, and 20% stained positive with antibody to the progesterone receptor. The proliferative index using a Ki-67 monoclonal antibody was 10%. HER-2/neu was not over-expressed (Figure 1). The nodular skin lesion was completely resected, and histopathological examination revealed it to be a SCC (grade II), infiltrating the hypodermis (Figure 2). Immediately after these surgical procedures, the patient was hospitalised in our institution where a cystoscopy was performed confirming ultrasound findings of multiple bladder papillary lesions arising from the posterior-lateral left wall, with a large base plant and active bleeding. A trans-urethral resection of the bladder lesion (TURB) was performed at the same time in which the neoplasm was completely excised. Subsequent histopathological examination showed a grade 3 papillary

66

67

68

69

70

71

72

73 74

75

76

77 78

79

80 **F2** 81

82

83

84


85

86

87

88

89



**Figure 2 Skin epithelial neoplasia. (A)** Low-power photomicrograph hypodermis infiltration, consisting of squamous cells arranged in solid nests and cords, with large areas of necrosis (magnification 4x); **(B)** High-power photomicrograph showing neoplastic cells characterized by moderately polymorphic nucleus, sometimes with evident nucleolus, large eosinophilic cytoplasm with ill-defined limits (magnification 40x).

114

90

91

92

93 F3

94

95

96 97

98 99

100

101

102

104

105

106

107

TCC that was in the process of infiltrating the muscular bladder wall (T2). The neoplastic cells were positive for cytokeratin 7 and negative for both cytokeratin 20 and Gross Cystic Disease Fluid Protein 15 (GCDFP-15) (Figure 3). Although a bone scan failed to find any skeletal metastasis, a whole body computed tomography (CT) scan revealed a diffuse thickening of the left bladder wall approximately 12.2 mm in diameter. This was found to be hypervascularised and in contact with the left vesicoureteral junction with minimal local infiltration of the perivesical area. There was also adenopathy in four retroperitoneal lymph nodes and concomitant left moderate hydroureteronephrosis. Therefore, the patient underwent total cystoprostatectomy with pelvic lymphadenectomy and a continent ileal urinary diversion. In consideration of the patient's age and overall physical condition, an orthotopic bladder replacement (neobladder reconstruction) using the Paduan technique was chosen.

After surgery, the patient received adjuvant therapy 108 (gemcitabine and cisplatin) for bladder and breast can-109 cer, which were considered the most important prognos-110 tic factors among the three neoplasms. He is currently 111 receiving adjuvant chemotherapy, including gemcitabine and cisplatin.

#### Discussion

In case of synchronous MPCs, it is important to consider the stages of the different neoplasms, their likely biological 116 behaviour, and the patient's age, life expectancy, and comorbidities as all of these can affect the treatment strategies and prognosis. The case we describe here met the 119 criteria of Warren and Gates [6], namely that each neoplasm must be a distinct malignancy and not a metastasis of the other. In this patient, three primary and histologically distinct cancers were found in three different organs, that is, primary TCC of the urinary bladder, SCC of the 124 skin on the forehead, and infiltrating ductal carcinoma of 125 the breast, all within a 2-month period. All these cancers 126 were considered primary neoplasms; thus, a diagnosis of 127 synchronous triple primary cancer was made. Synchronous neoplasms are defined as ≥2 primary neoplasms diagnosed within 6 months of each other, while metachronous neoplasms are defined as those detected after an interval 131 of >6 months [5]. A patient with a history of cancer may have an increased risk of developing another neoplasm due to exposure to common carcinogenic factors, such as tobacco and alcohol, or genetic predisposition (for example, Li-Fraumeni or Beckwith-Wiedemann syndrome), or as a side-effect of previous chemotherapy or radiotherapy [8]. In




Figure 3 Bladder cancer. (A) Low-power photomicrograph showing malignant bladder epithelial proliferation organized in papillary structures, nests, sometimes with central necrosis, solid and cords that diffusely infiltrate subepithelial corium and the muscularis (magnification 4x); (B) High-power photomicrograph showing epithelial cells of medium-great size, with altered nucleus-cytoplasm ratio, leptocromatinic nucleus, nucleolus often prominent and large eosinophilic cytoplasm (magnification 40x); the cells resulted negative to immunohistochemical staining for GCDFP-15 (C), positive for CK7 (D) and negative per CK20 (E) (magnification 40x).

101

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215 216

217

218

219

220

221

223

224

225

226 227

228

the current case, three likely causal factors were that the pa-138 tient was a heavy, chronic smoker, that he had been ex-139 posed to chemicals, especially those in pesticides, and that 140 he had experienced prolonged exposure to ultraviolet radi-141 ation from working outside. Gallagher et al. suggested that 142 prior exposure to insecticides, herbicides, and fungicides or 143 seed treatments are associated with an increased incidence 144 145 of SCC of the skin [9]. No other predisposing factor or a family history was found that might have contributed to the 146 147 development of these three neoplasms.

To our knowledge, this is the first reported case in the 148 literature reporting this combination of primary neo-149 plasms, although Pastore et al. previously described a case 150 of synchronous ureteral and bladder metastases arising 151 from infiltrating ductal breast carcinoma in an elderly 152 woman [10]. We suggest that the onset of multiple pri-153 mary neoplasms are the result of a combination of differ-154 ent factors, including improved cancer survival rates 155 increasing the length of time over which additional can-156 cers can develop [5]. 157

### 158 Conclusions

The incidence of MPC is probably influenced by a combination of environmental and genetic factors, and the prognosis for a patient with multiple malignancies is most probably determined by whichever neoplasm is the most aggressive. To the best of our knowledge, this is the first case in the literature to report distinct bladder, breast and skin primary neoplasms in the same patient.

#### 166 Consent

- 167 Written informed consent was obtained from the patient 168 for publication of the case report and any accompanying
- 169 images. A copy of written consent is available for review
- 170 by the Editor-in-Chief of this journal.

#### 171 Abbreviations

- 72 CT: Computed tomography; MPC: Multiple primary cancers; SCC: Squamous
- 173 cell carcinoma; TCC: Transitional cell carcinoma; TURB: Transurethral resection
- 174 of bladder.

# 175 Competing interests

176 The authors declare that they have no competing interests.

# 177 Authors' contributions

- 178 ALP, GP, AL, LS, AD, KS, AR, CM, NP, DM and AF were involved in the review
- 179 of literature, acquisition of data and drafting and completing the manuscript.
- 180 AC, CDR, VP and CDC conceived the study, participated in the co-ordination
- and the acquisition of data, and helped to draft the manuscript. All authors
- 182 read and approved the final version of the manuscript.

#### 183 Acknowledgements

- 184 The authors declare that this research received no specific grant from any
- 185 funding agency in the public, commercial, or not-for-profit sectors. The
- 86 authors have no conflicts of interest to disclose.

# 187 Author details

- 188 <sup>1</sup>Department of Medical and Surgical Sciences and Biotechnologies, Unit of
- 189 Urology, Faculty of Pharmacy and Medicine, Sapienza University of Rome,
- 190 Corso della Repubblica 79, 04100, Latina, (LT), Italy. <sup>2</sup>Department of Medical-

Surgical Sciences and Biotechnologies, Histopathology Unit-I.C.O.T, Latina,
Italy. <sup>3</sup> Department of Medical-Surgical Sciences and Biotechnologies,
Oncology Unit-I.C.O.T, Latina, Italy.

#### Received: 23 April 2013 Accepted: 30 September 2013 Published: 20 October 2013

#### References

- Billroth T: [General surgical pathology and therapy. Guidance for students and physicians. Lecture]. Khirurqija (Mosk) 1991, 10(10):136–143.
- Tiwari P, Tripathi A, Bansal P, Vijay M, Gupta A, Kundu AK: Synchronous primary cancers of urinary bladder and kidney and prostate. Saudi J Kidney Dis Transpl 2012, 23:786–789.
- Otrock ZK, Mahfouz RA, Salem ZM: Four primary tumors of lung, bladder, prostate, and breast in a male patient. South Med J 2005, 98:946–949.
- Komiyama S, Nishio E, Ichikawa R, Miyamura H, Kawamura K, Komiyama M, Nishio Y, Udagawa Y: Asymptomatic synchronous quintuple primary cancers. Gynecol Obstet Invest 2012, 74:324–328.
- Koutsopoulos AV, Dambaki KI, Datseris G, Giannikaki E, Froudarakis M, Stathopoulos E: A novel combination of multiple primary carcinomas: Urinary bladder transitional cell carcinoma, prostate adenocarcinoma and small cell lung carcinoma-report of a case and review of the literature. World J Surg Oncol 2005, 3:51.
- Warren S, Gates O: Multiple primary malignant tumors. A survey of the literature and a statistical study. Amer J Cancer 1932, 16:1358–1414.
- Ray P, Sharifi R, Ortolano V, Guinan P: Involvement of the genitourinary system in multiple primary malignant neoplasms: a review. J Clin Oncol 1983, 1:574.
- Rabbani F, Grimaldi G, Russo P: Multiple primary malignancies in renal cell carcinoma. J Urol 1998, 160:1255–1259.
- Gallagher RP, Bajdik CD, Fincham S: Chemical exposures, medical history, and risk of squamous and basal cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev 1996, 5:419

  –424.
- Pastore AL, Palleschi G, Tubaro A, De Nunzio C, Stoppaciaro A, Silvestri L, Serafini GM, Stagnitti F, Carbone A: Synchronous urinary tract metastases from breast cancer. *Urologia* 2009, 76:66–67.

# doi:10.1186/1477-7819-11-282

Cite this article as: Pastore et al.: Synchronous primary neoplasms of the bladder, skin and breast in a male patient: a case report. World Journal of Surgical Oncology 2013 11:282.

# Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

